{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:27Z","timestamp":1792783227103,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"J-Pharma Co., Ltd.","id":[{"id":"https:\/\/ror.org\/05b2z2644","id-type":"ROR","asserted-by":"crossref"}]},{"name":"JSPS KAKENHI Grants-in-Aid for Scientific Research","award":["22H02781"],"award-info":[{"award-number":["22H02781"]}]},{"name":"JST SPRING","award":["JPMJSP2135"],"award-info":[{"award-number":["JPMJSP2135"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"DOI":"10.1007\/s11095-026-04223-z","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:23Z","timestamp":1792106543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-lasting Inhibition of L-type Amino Acid Transporter 1 by Nanvuranlat is Associated with Prolonged Cellular Retention Counteracted by Cancer-type OATP1B3 in Cholangiocarcinoma Cells"],"prefix":"10.1007","author":[{"given":"Kiyoshi","family":"Oka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Masuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunosuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuhiro","family":"Yoshitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-5679","authenticated-orcid":false,"given":"Yukio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"1","key":"4223_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4251\/wjgo.v9.i1.21","volume":"9","author":"K Hayashi","year":"2017","unstructured":"Hayashi K, Anzai N. Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol. 2017;9(1):21\u20139. https:\/\/doi.org\/10.4251\/wjgo.v9.i1.21.","journal-title":"World J Gastrointest Oncol"},{"issue":"6","key":"4223_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960\u201376. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004.","journal-title":"Cell"},{"issue":"9","key":"4223_CR3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1158\/0008-5472.CAN-14-3745","volume":"75","author":"YD Bhutia","year":"2015","unstructured":"Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino acid transporters in cancer and their relevance to \u201cglutamine addiction\u201d: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75(9):1782\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3745.","journal-title":"Cancer Res"},{"issue":"3","key":"4223_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2009.01.021","volume":"136","author":"A Cohen","year":"2009","unstructured":"Cohen A, Hall MN. An amino acid shuffle activates mTORC1. Cell. 2009;136(3):399\u2013400. https:\/\/doi.org\/10.1016\/j.cell.2009.01.021.","journal-title":"Cell"},{"issue":"1","key":"4223_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-482","volume":"13","author":"K Kaira","year":"2013","unstructured":"Kaira K, Sunose Y, Ohshima Y, et al. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 2013;13(1):482. https:\/\/doi.org\/10.1186\/1471-2407-13-482.","journal-title":"BMC Cancer"},{"issue":"4","key":"4223_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/bjc.2012.310","volume":"107","author":"K Kaira","year":"2012","unstructured":"Kaira K, Sunose Y, Arakawa K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012;107(4):632\u20138. https:\/\/doi.org\/10.1038\/bjc.2012.310.","journal-title":"Br J Cancer"},{"issue":"4","key":"4223_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/sj.bjc.6604235","volume":"98","author":"K Kaira","year":"2008","unstructured":"Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98(4):742\u20138. https:\/\/doi.org\/10.1038\/sj.bjc.6604235.","journal-title":"Br J Cancer"},{"issue":"1","key":"4223_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1349-7006.2009.01386.x","volume":"101","author":"K Oda","year":"2010","unstructured":"Oda K, Hosoda N, Endo H, et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010;101(1):173\u20139. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01386.x.","journal-title":"Cancer Sci"},{"issue":"7","key":"4223_CR9","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/cas.16191","volume":"115","author":"S Saito","year":"2024","unstructured":"Saito S, Ando K, Sakamoto S, et al. The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism. Cancer Sci. 2024;115(7):2461\u201372. https:\/\/doi.org\/10.1111\/cas.16191.","journal-title":"Cancer Sci"},{"issue":"20","key":"4223_CR10","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1111\/jcmm.17553","volume":"26","author":"K Nishikubo","year":"2022","unstructured":"Nishikubo K, Ohgaki R, Okanishi H, et al. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. J Cell Mol Med. 2022;26(20):5246\u201356. https:\/\/doi.org\/10.1111\/jcmm.17553.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4223_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01762-0","volume":"39","author":"L Quan","year":"2020","unstructured":"Quan L, Ohgaki R, Hara S, et al. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation. J Exp Clin Cancer Res. 2020;39(1):266. https:\/\/doi.org\/10.1186\/s13046-020-01762-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"4223_CR12","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","volume":"38","author":"N Okano","year":"2020","unstructured":"Okano N, Naruge D, Kawai K, et al. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020;38(5):1495\u2013506. https:\/\/doi.org\/10.1007\/s10637-020-00924-3.","journal-title":"Invest New Drugs"},{"issue":"18","key":"4223_CR13","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-24-0461","volume":"30","author":"J Furuse","year":"2024","unstructured":"Furuse J, Ikeda M, Ueno M, et al. A phase II placebo-controlled study of the effect and safety of nanvuranlat in patients with advanced biliary tract cancers previously treated by systemic chemotherapy. Clin Cancer Res. 2024;30(18):3990\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0461.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4223_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.21873\/anticanres.13092","volume":"39","author":"Y Muto","year":"2019","unstructured":"Muto Y, Furihata T, Kaneko M, et al. Different response profiles of gastrointestinal cancer cells to an L-type amino acid transporter inhibitor, JPH203. Anticancer Res. 2019;39(1):159\u201365. https:\/\/doi.org\/10.21873\/anticanres.13092.","journal-title":"Anticancer Res"},{"issue":"2","key":"4223_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/cas.14756","volume":"112","author":"H Okanishi","year":"2021","unstructured":"Okanishi H, Ohgaki R, Okuda S, Endou H, Kanai Y. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor. Cancer Sci. 2021;112(2):871\u201383. https:\/\/doi.org\/10.1111\/cas.14756.","journal-title":"Cancer Sci"},{"key":"4223_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS18152492","author":"EK Rowinsky","year":"2026","unstructured":"Rowinsky EK, Abou-Alfa GK, Furuse J, et al. Clinical and LAT1 biomarker correlates of clinical benefit from nanvuranlat (JPH203) in advanced biliary tract cancer: a post hoc analysis. Cancers (Basel). 2026. https:\/\/doi.org\/10.3390\/CANCERS18152492.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4223_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-87522-6","volume":"15","author":"C Jin","year":"2025","unstructured":"Jin C, Zhou X, Xu M, Okanishi H, Ohgaki R, Kanai Y. Pharmacological and structural insights into nanvuranlat, a selective LAT1 (SLC7A5) inhibitor, and its N-acetyl metabolite with implications for cancer therapy. Sci Rep. 2025;15(1):2903. https:\/\/doi.org\/10.1038\/s41598-025-87522-6.","journal-title":"Sci Rep"},{"issue":"1","key":"4223_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jphs.2020.06.006","volume":"144","author":"K Okunushi","year":"2020","unstructured":"Okunushi K, Furihata T, Morio H, et al. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function. J Pharmacol Sci. 2020;144(1):16\u201322. https:\/\/doi.org\/10.1016\/j.jphs.2020.06.006.","journal-title":"J Pharmacol Sci"},{"issue":"9","key":"4223_CR19","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1002\/jps.23601","volume":"102","author":"J Toyoshima","year":"2013","unstructured":"Toyoshima J, Kusuhara H, Wempe MF, Endou H, Sugiyama Y. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203. J Pharm Sci. 2013;102(9):3228\u201338. https:\/\/doi.org\/10.1002\/jps.23601.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4223_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2133\/dmpk.dmpk-11-rg-091","volume":"27","author":"MF Wempe","year":"2012","unstructured":"Wempe MF, Rice PJ, Lightner JW, et al. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. Drug Metab Pharmacokinet. 2012;27(1):155\u201361. https:\/\/doi.org\/10.2133\/dmpk.dmpk-11-rg-091.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"4223_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-014-0037-y","volume":"3","author":"Y Sun","year":"2014","unstructured":"Sun Y, Furihata T, Ishii S, et al. Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers. Clin Transl Med. 2014;3(1):e37. https:\/\/doi.org\/10.1186\/s40169-014-0037-y.","journal-title":"Clin Transl Med"},{"issue":"11","key":"4223_CR22","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1007\/s11095-013-1117-1","volume":"30","author":"S Imai","year":"2013","unstructured":"Imai S, Kikuchi R, Tsuruya Y, et al. Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res. 2013;30(11):2880\u201390. https:\/\/doi.org\/10.1007\/s11095-013-1117-1.","journal-title":"Pharm Res"},{"key":"4223_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118402","volume":"190","author":"V Morozova","year":"2025","unstructured":"Morozova V, Pellegata D, Singer S, et al. Pharmacodynamic analyses of LAT1 inhibitors in vitro and in vivo by targeted metabolomics reveal target-independent effects. Biomed Pharmacother. 2025;190:118402. https:\/\/doi.org\/10.1016\/j.biopha.2025.118402.","journal-title":"Biomed Pharmacother"},{"key":"4223_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107046","volume":"209","author":"\u00c9 Bakos","year":"2025","unstructured":"Bakos \u00c9, Bujdos\u00f3-Sz\u00e9kely V, Patik I, et al. Cancer-type OATP1B3-V1 is a functional plasma membrane transporter mediating increased uptake of chemotherapeutics in vitro and in vivo. Eur J Pharm Sci. 2025;209:107046. https:\/\/doi.org\/10.1016\/j.ejps.2025.107046.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"4223_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.bbrc.2012.01.115","volume":"418","author":"M Nagai","year":"2012","unstructured":"Nagai M, Furihata T, Matsumoto S, et al. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun. 2012;418(4):818\u201323. https:\/\/doi.org\/10.1016\/j.bbrc.2012.01.115.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4223_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1021\/mp3005353","volume":"10","author":"N Thakkar","year":"2013","unstructured":"Thakkar N, Kim K, Jang ER, et al. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406\u201316. https:\/\/doi.org\/10.1021\/mp3005353.","journal-title":"Mol Pharm"},{"issue":"6","key":"4223_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1124\/molpharm.122.000539","volume":"102","author":"B Haberkorn","year":"2022","unstructured":"Haberkorn B, Oswald S, Kehl N, et al. Cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3) is localized in lysosomes and mediates resistance against kinase inhibitors. Mol Pharmacol. 2022;102(6):248\u201358. https:\/\/doi.org\/10.1124\/molpharm.122.000539.","journal-title":"Mol Pharmacol"},{"key":"4223_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bcp.2017.02.013","volume":"131","author":"SE Chun","year":"2017","unstructured":"Chun SE, Thakkar N, Oh Y, et al. The N-terminal region of organic anion transporting polypeptide 1B3 (OATP1B3) plays an essential role in regulating its plasma membrane trafficking. Biochem Pharmacol. 2017;131:98\u2013105. https:\/\/doi.org\/10.1016\/j.bcp.2017.02.013.","journal-title":"Biochem Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04223-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04223-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04223-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:25Z","timestamp":1792106545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04223-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":28,"alternative-id":["4223"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04223-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tokiko Suzuki, Kazuo Sekiguchi, and Masuhiro Yoshitake are employees of J-Pharma Co., Ltd. Kiyoshi Oka, Yusuke Masuo, Atsunosuke Yamada, and Yukio Kato declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}